Evidence map›Paper›PMID 24124966›Full record

ReviewJournal of diabetes science and technology2013

Average daily risk range as a measure for clinical research and routine care.

Susana R Patton, Mark A Clements

Abstract readReview
In one paragraph

Review in Journal of diabetes science and technology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Observational
  4. Article
  5. Article
  6. Article
  7. The Role of Glycemic Variability in Cardiovascular Disorders.International journal of molecular sciences · 2021
    Review
  8. Review
  9. Metrics for glycaemic control - from HbANature reviews. Endocrinology · 2017 · on this map
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Susana R PattonUniversity of Kansas Medical Center, MS 4004, 3901 Rainbow Blvd., Kansas City, KS 66160. spatton2@kumc.edu.
Mark A Clements

Funding

Improving Mealtime Functioning in Families of Young Children with Type 1 DiabetesK23DK076921 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PATTON, SUSANA R · 2007 to 2011
$566k
NIDDK NIH HHS K23-DK076921
6 · The paper itself

Abstract

There is emerging evidence suggesting that glycemic variability may relate to risk for diabetes-related complications. This article provides a description of average daily risk range (ADRR), a diabetes-specific measure of risk for hyperglycemia and hypoglycemia, and provides a summary of research using ADRR and clinical applications of ADRR. Average daily risk range is a variability metric that is based on "risk" values obtained from glucose levels that are mathematically transformed to give equal weight to hyperglycemic and hypoglycemic excursions. It can be calculated using self-monitoring of blood glucose or continuous glucose monitoring (CGM) data. The ADRR is scored based on risk categories: low risk, 0-19; moderate risk, 20-40; and high risk, 40 and above. Research using ADRR has found it to be a reliable predictor of extreme blood glucose values regardless of diabetes type and patients' age. Moreover, in treatment studies, ADRR presents as a very conservative measure of variability. Clinically, ADRR can provide meaningful data related to patients' risk for hyperglycemia and hypoglycemia that is not available from glycated hemoglobin values. Average daily risk range scores may also help clinicians to identify patients who may be overtreating blood glucose levels, leading to very high or low values. To expand the utility of ADRR, future research should examine the validity of existing risk cutoff scores for pediatric patients, determine if ADRR cutoff scores need to be modified for CGM data, and investigate whether patients' ADRR scores also relate to the development of long-term complications, including retinopathy and microalbuminuria.

Indexed as

Blood GlucoseDiabetes MellitusHumansHyperglycemiaHypoglycemiaRiskBlood Glucose

Identifiers

PMID24124966
PMCPMC3876383

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.